HBM Holdings Partner Doses First Patient in SKB378 COPD Study

MT Newswires Live

06/10

HBM Holdings (HKG:2142) said its partner, Windward Bio, dosed the first patient in a phase II study of SKB378 for chronic obstructive pulmonary disease, according to a Tuesday filing with the Hong Kong bourse.

The drug, also known as HBM9378/WIN378, is also being evaluated in a separate phase II/III asthma study, with initial phase II data expected in the second half of 2026.

The first phase III study of the drug in asthma is expected to begin in the final quarter of 2026.

In a separate filing, HBM Holdings said Chinese regulators accepted the investigational new drug application for HBM7004.

The firm is seeking approval to begin trials of the drug in patients with advanced solid tumors.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2642410373"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2642410373\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2642410373?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 13:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642410373","market":"nz","top_or_hot":-1,"title":"HBM Holdings Partner Doses First Patient in SKB378 COPD Study","media":"MT Newswires Live","content":"<html><body><p> HBM Holdings (HKG:2142) said its partner, Windward Bio, dosed the first patient in a phase II study of SKB378 for chronic obstructive pulmonary disease, according to a Tuesday filing with the Hong Kong bourse.</p><p>The drug, also known as HBM9378/WIN378, is also being evaluated in a separate phase II/III asthma study, with initial phase II data expected in the second half of 2026.</p><p>The first phase III study of the drug in asthma is expected to begin in the final quarter of 2026.</p><p>In a separate filing, HBM Holdings said Chinese regulators accepted the investigational new drug application for HBM7004.</p><p>The firm is seeking approval to begin trials of the drug in patients with advanced solid tumors.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings Partner Doses First Patient in SKB378 COPD Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings Partner Doses First Patient in SKB378 COPD Study\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-06-10 13:47</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> HBM Holdings (HKG:2142) said its partner, Windward Bio, dosed the first patient in a phase II study of SKB378 for chronic obstructive pulmonary disease, according to a Tuesday filing with the Hong Kong bourse.</p><p>The drug, also known as HBM9378/WIN378, is also being evaluated in a separate phase II/III asthma study, with initial phase II data expected in the second half of 2026.</p><p>The first phase III study of the drug in asthma is expected to begin in the final quarter of 2026.</p><p>In a separate filing, HBM Holdings said Chinese regulators accepted the investigational new drug application for HBM7004.</p><p>The firm is seeking approval to begin trials of the drug in patients with advanced solid tumors.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2642410373","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642410373","pubTimestamp":1781070453,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"HBM Holdings  said its partner, Windward Bio, dosed the first patient in a phase II study of SKB378 for chronic obstructive pulmonary disease, according to a Tuesday filing with the Hong Kong bourse.The drug, also known as HBM9378/WIN378, is also being evaluated in a separate phase II/III asthma study, with initial phase II data expected in the second half of 2026.The first phase III study of the drug in asthma is expected to begin in the final quarter of 2026.In a separate filing, HBM Holdings said Chinese regulators accepted the investigational new drug application for HBM7004.The firm is seeking approval to begin trials of the drug in patients with advanced solid tumors.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","02142":"和铂医药-B","BK1161":"生物科技","BK4588":"碎股","DRAM":"Roundhill Memory ETF","BK1574":"生物医药B类股"},"translate_title":"HBM Holdings合作伙伴为SKB378 COPD研究中的首例患者进行给药","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DRAM":1.5,"02142":1},"content_text":"HBM Holdings (HKG:2142) said its partner, Windward Bio, dosed the first patient in a phase II study of SKB378 for chronic obstructive pulmonary disease, according to a Tuesday filing with the Hong Kong bourse.The drug, also known as HBM9378/WIN378, is also being evaluated in a separate phase II/III asthma study, with initial phase II data expected in the second half of 2026.The first phase III study of the drug in asthma is expected to begin in the final quarter of 2026.In a separate filing, HBM Holdings said Chinese regulators accepted the investigational new drug application for HBM7004.The firm is seeking approval to begin trials of the drug in patients with advanced solid tumors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}